Health Information Management

Tip: Note new Q codes

APCs Insider, August 31, 2012

Want to receive articles like this one in your inbox? Subscribe to APCs Insider!

CMS added the following six HCPCS codes to the I/OCE effective July 1:

  • Q2045, injection, human fibrinogen concentrate, 1 mg
  • Q2046, injection, aflibercept, 1 mg
  • Q2047, injection, Peginesatide, 0.1 mg (for ESRD on dialysis)
  • Q2048, injection, doxorubicin hydrochloride, ­liposomal, doxil, 10 mg
  • Q2049, injection, doxorubicin hydrochloride, ­liposomal, imported lipodox, 10 mg
  • Q2034, influenza virus vaccine, split virus, for ­intramuscular use (Agriflu)
Three of the codes replaced other HCPCS Level II codes. Code Q2045 replaced code J1680 (injection, human fibrinogen concentrate, 100 mg) July 1. Code Q2046 replaced C9291 (injection, aflibercept, 2 mg vial), and code Q2048 replaced J9001 (injection, doxorubicin hydrochloride, all lipid formulations, 10 mg).
 
Codes Q2045, Q2048, and Q2049 all have status indicator K (paid under OPPS; separate APC payment). Code Q2046 is assigned status indicator G (pass-through drugs and biologicals). Code Q2047 has status indicator A (services furnished to a hospital outpatient that are paid under a fee schedule or payment system other than OPPS). Code Q2034 falls under status indicator L (influenza vaccine; pneumococcal pneumonia vaccine).
 
The tip is adapted from “Device-to-procedure edit reinstated, new codes added” in the August Briefings on APCs.



Want to receive articles like this one in your inbox? Subscribe to APCs Insider!

Most Popular